Spruce Biosciences Statistics
Share Statistics
Spruce Biosciences has 41.30M shares outstanding. The number of shares has increased by 1.45% in one year.
| Shares Outstanding | 41.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.36M |
| Failed to Deliver (FTD) Shares | 5.83K |
| FTD / Avg. Volume | 1.01% |
Short Selling Information
The latest short interest is 232.77K, so 0.56% of the outstanding shares have been sold short.
| Short Interest | 232.77K |
| Short % of Shares Out | 0.56% |
| Short % of Float | 0.85% |
| Short Ratio (days to cover) | 0.43 |
Valuation Ratios
The PE ratio is -2.35 and the forward PE ratio is -0.58.
| PE Ratio | -2.35 |
| Forward PE | -0.58 |
| PS Ratio | 11.18 |
| Forward PS | 37.4 |
| PB Ratio | 1.47 |
| P/FCF Ratio | -3.39 |
| PEG Ratio | n/a |
Enterprise Valuation
Spruce Biosciences Inc. has an Enterprise Value (EV) of 21.10M.
| EV / Earnings | -0.44 |
| EV / Sales | 2.09 |
| EV / EBITDA | -0.45 |
| EV / EBIT | -0.41 |
| EV / FCF | -0.63 |
Financial Position
The company has a current ratio of 4.18, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.18 |
| Quick Ratio | 4.18 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 4.18 |
| Cash Flow / Debt | -9.97 |
| Interest Coverage | -107.65 |
Financial Efficiency
Return on equity (ROE) is -0.63% and return on capital (ROIC) is -64.1%.
| Return on Equity (ROE) | -0.63% |
| Return on Assets (ROA) | -0.46% |
| Return on Capital (ROIC) | -64.1% |
| Revenue Per Employee | 347.90K |
| Profits Per Employee | -1.65M |
| Employee Count | 29 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -76.51% in the last 52 weeks. The beta is 2.37, so Spruce Biosciences 's price volatility has been higher than the market average.
| Beta | 2.37 |
| 52-Week Price Change | -76.51% |
| 50-Day Moving Average | 0.51 |
| 200-Day Moving Average | 0.79 |
| Relative Strength Index (RSI) | 29.08 |
| Average Volume (20 Days) | 578.34K |
Income Statement
In the last 12 months, Spruce Biosciences had revenue of $10.09M and earned -$47.92M in profits. Earnings per share was $-1.24.
| Revenue | 10.09M |
| Gross Profit | -39.34M |
| Operating Income | -51.99M |
| Net Income | -47.92M |
| EBITDA | -47.37M |
| EBIT | -51.99M |
| Earnings Per Share (EPS) | -1.24 |
Balance Sheet
The company has $96.34M in cash and $4.61M in debt, giving a net cash position of $91.73M.
| Cash & Cash Equivalents | 96.34M |
| Total Debt | 4.61M |
| Net Cash | 91.73M |
| Retained Earnings | -197.23M |
| Total Assets | 65.10M |
| Working Capital | 51.72M |
Cash Flow
In the last 12 months, operating cash flow was -$33.27M and capital expenditures -$7.00K, giving a free cash flow of -$33.28M.
| Operating Cash Flow | -33.27M |
| Capital Expenditures | -7.00K |
| Free Cash Flow | -33.28M |
| FCF Per Share | -0.86 |
Margins
Gross margin is -389.96%, with operating and profit margins of -515.34% and -474.96%.
| Gross Margin | -389.96% |
| Operating Margin | -515.34% |
| Pretax Margin | -474.96% |
| Profit Margin | -474.96% |
| EBITDA Margin | -469.48% |
| EBIT Margin | -515.34% |
| FCF Margin | -329.88% |
Dividends & Yields
SPRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -317.95% |
| FCF Yield | -209.19% |
Analyst Forecast
The average price target for SPRB is $2, which is 412.8% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 412.8% |
| Analyst Consensus | Hold |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -5.08 |
| Piotroski F-Score | 4 |